0001209191-20-023793.txt : 20200407
0001209191-20-023793.hdr.sgml : 20200407
20200407170858
ACCESSION NUMBER: 0001209191-20-023793
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200403
FILED AS OF DATE: 20200407
DATE AS OF CHANGE: 20200407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arjona Ferreira Juan Camilo
CENTRAL INDEX KEY: 0001714080
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37929
FILM NUMBER: 20780375
MAIL ADDRESS:
STREET 1: C/O MYOVANT SCIENCES INC.
STREET 2: 2000 SIERRA POINT PARKWAY, 9TH FLOOR
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER NAME:
FORMER CONFORMED NAME: Ferreira Juan Camilo Arjona
DATE OF NAME CHANGE: 20170807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Myovant Sciences Ltd.
CENTRAL INDEX KEY: 0001679082
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: CA
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 207-400-3351
MAIL ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-03
0
0001679082
Myovant Sciences Ltd.
MYOV
0001714080
Arjona Ferreira Juan Camilo
C/O MYOVANT SCIENCES INC.
2000 SIERRA POINT PARKWAY, 9TH FLOOR
BRISBANE
CA
94005
0
1
0
0
Chief Medical Officer
Common Shares
2020-04-03
4
A
0
87805
0.00
A
145115
D
Employee Stock Option (Right to Buy)
8.08
2020-04-03
4
A
0
134464
0.00
A
2030-04-02
Common Shares
134464
134464
D
The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 3, 2021, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.
1/4 of the common shares underlying this option vest on April 3, 2021, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.
/s/ Matthew Lang, Attorney-in-Fact
2020-04-07